Company intelligence / Profile preview

Igenica Biotherapeutics

Burlingame, California, United Statesigenica.com ↗

Ownership: Private
Employees: ~3
Development stage: Other

Overview

The company had a promising anti-cancer antibody in Phase 1 clinical trial before being acquired. Their lead product candidates included IGN523 (a humanized monoclonal antibody for multiple hematologic and solid tumors), IGN786 (targeting a novel target called SAIL), and IGN381 (targeting an immune checkpoint)

Therapeutic areas: OncologyHematology
Modalities: AntibodiesAntibody-drug conjugates (ADCs)Immunotherapies
Industry: Biotech

Partnerships

Academic institutionsgovernment agenciespharmaceutical companies

Beyond the preview

Go deeper on Igenica Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Igenica Biotherapeutics.